Clinical trials: Cardiotoxicity
Cardiotoxicity, Breast Cancer
PROactive Evaluation of Function to Avoid CardioToxicity
This study is intended to evaluate the ability of an intramyocardial strain analysis package with cardiac MRI to assist in the early detection and management of cardiotoxicity from therapeutics used to treat cancer.
- Conditions
- Cardiotoxicity, Breast Cancer, Lymphoma, Sarcoma
- Trial name
- PROACT (NCT03862131)
- Testing
- MyoStrain®
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Washington University School of Medicine
Breast Neoplasms
Using Hyperpolarized [1-13C]Pyruvate to Detect Cardiotoxicity
The anthracycline doxorubicin, first introduced in the 1960's, continues to be an effectively utilized antineoplastic drug. Even at relatively low cumulative doses there is risk of cardiotoxicity.
- Trial name
- HPCardiotox (NCT03685175)
- Testing
- Formal study using hyperpolarized 13C-pyruvate injection, Feasible study using hyperpolarized 13C-pyruvate injection
- Where
- United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Radiation Toxicity
Oligo-Fucoidan Decrease Lung Radiation Damage
Fucoidan is FDA approved and in common use for treatment of angina. These studies will advance that work to human use. Successful mitigation of lung radiation damage and heart toxicity will improve the quality of life in veterans…
- Trial name
- FIRILI (NCT05616507)
- Testing
- fucoidan
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Taipei Medical University WanFang Hospital
Cardiac Toxicity, Early-stage Breast Cancer
Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted
This study proposes that the addition of statins reduces the treatment delays or early discontinuations secondary to cardiotoxicity in patients with Stage I-III HER2 positive breast being treated with anti-HER2 therapy.
- Trial name
- NCT05559164
- Testing
- Lipitor 40mg Tablet
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Rutgers, The State University of New Jersey
Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung), Drug-Related Side Effects and Adverse Reactions (MeSH Term)
Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung Cancer
This study investigated the incidence of cardiac dysfunction in patients with advanced or recurrent epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer treated with EGFR- tyrosine kinase inhibitors.
- Conditions
- Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung), Drug-Related Side Effects and Adverse Reactions (MeSH Term), Egfr Tyrosine Kinase Inhibitor, Cardiotoxicity
- Trial name
- NCT07267247
- Testing
- EGFR-TKI, EGFR tyrosine kinase inhibitor
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Taichung Veterans General Hospital
Non Small Cell Lung Cancer, Cardiotoxicity
Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Prospective clinical study designed to evaluate damage to the heart after receiving standard of care chemotherapy and radiation therapy for locally advanced Non-Small Cell Lung Cancer (NSCLC).
- Conditions
- Non Small Cell Lung Cancer, Cardiotoxicity, Locally Advanced Non-Small Cell Lung Cancer, Radiation Therapy
- Trial name
- NCT07761910
- Testing
- PET/CT 18F-Flurpiridaz Rest/Stress Test, Coronary CT Angiography (CCTA), 18F-Flurpiridaz
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Indiana University
Non-Hodgkin's Lymphoma
Prevention of CHOP-induced Chronic Cardiotoxicity
The purpose of this study is to assess the protective effect of Valsartan on chronic cardiotoxicity induced by CHOP.
- Trial name
- NCT00162955
- Testing
- Valsartan
- Where
- Japan
- Volunteers
- 150 people
- Sponsor
- Osaka City University
Left Ventricular Function Systolic Dysfunction, Cardiotoxicity
Usefulness of Myocardial Deformation Imaging for Trastuzumab-induced Cardiotoxicity
Trastuzumab prolongs survival in patients with human epidermal growth factor receptor type 2-positive breast cancer. Sequential left ventricular (LV) ejection fraction (EF) assessment has been mandated to detect myocardial…
- Trial name
- NCT01665300
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- Seoul National University Hospital
Breast Cancer
Evaluating the Effect of Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity
Evaluating the effect of the angiotensin II-receptor (AT1) blocker candesartan vs placebo in prevention of trastuzumab-associated cardiotoxicity in patients with primary breast cancer treated with trastuzumab.
- Trial name
- NCT00459771
- Testing
- AT1 blocker candesartan
- Where
- 19 sites in Netherlands
- Volunteers
- 210 people
- Sponsor
- The Netherlands Cancer Institute
Cardiotoxicity
Artificial Intelligence for Reconstruction of Echocardiography Studies
To investigate the clinical utility of both 3D and 2D artificial intelligence reconstruction echocardiography (V-echo and L-echo) assessment against conventional echocardiography and clinical cardiovascular magnetic resonance…
- Trial name
- AIRES (NCT07093918)
- Testing
- V-echo, L-echo
- Volunteers
- 120 people
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Chemotherapeutic Toxicity, Cardiotoxicity
Strategy Therapy on Cancer Therapy-Related Cardiac Dysfunction
The investigators use the cancer registration system of National Cheng Kung University Hospital to timely screen and evaluate those patients having breast cancer or lymphoma to enroll patients to participate in this clinical…
- Conditions
- Chemotherapeutic Toxicity, Cardiotoxicity, Heart Failure, Breast Cancer
- Trial name
- NCT05892146
- Testing
- Prevention therapy, Rescue therapy
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Cheng-Kung University Hospital
Cardiotoxicity
Early Detection of Cardiotoxicity From Systemic and Radiation Therapy in Breast Cancer Patients
To assess the role of myocardial oedema on CMR (T2 mapping) after radiation therapy and cardiotoxic systemic therapy in predicting the incidence of cardiotoxicity, defined as by consensus guidelines* (decline of LVEF ≥10% points…
- Trial name
- CARDIOTOX (NCT04790266)
- Testing
- Cardiac MRI
- Where
- Switzerland
- Volunteers
- 150 people
- Sponsor
- Oncology Institute of Southern Switzerland
Lymphoma, Heart Failure, Congestive
Early Assessment of Anthracycline-induced Cardiotoxicity (CARDIOTOX)
Anthracycline-based chemotherapy is a key point of the treatment of patients with Hodgkin's and non-Hodgkin's lymphomas. However, cumulative doses are limited by cardiotoxicity, resulting in a marked left ventricular function…
- Trial name
- NCT00195897
- Where
- 2 sites in France
- Volunteers
- 6 people
- Sponsor
- Centre Henri Becquerel
Breast Cancer, Cardiotoxicity
A Study of Blood Pressure Control During Cancer Treatment
The purpose of this study to find out whether an intensive approach to treating high blood pressure during breast cancer treatment is safe and more effective than standard blood pressure treatment at lowering blood pressure…
- Trial name
- NCT06023576
- Testing
- antihypertensive medications, Blood pressure measurement, Echocardiogram
- Where
- 7 sites in United States
- Volunteers
- 130 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cardiotoxicity, Breast Cancer
Dietary Restriction to Prevent Cardiotoxicity in Breast Cancer Patients
The goal of this clinical trial is to compare a dietary intervention with a regular diet in patients with early breast cancer undergoing anthracycline based chemotherapy.
- Trial name
- PROTECT-COR (NCT06622954)
- Testing
- Protein- and Calorie restriction
- Where
- Netherlands
- Volunteers
- 32 people
- Sponsor
- Erasmus Medical Center
Breast Cancer
Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy
The activity of trastuzumab in early-stage, HER2-positive breast cancer, has been demonstrated in many studies, with meta-analyses showing that in combination with a variety of chemotherapy backbones, trastuzumab reduces the risk…
- Trial name
- NCT04928261
- Testing
- Trastuzumab
- Where
- Canada
- Volunteers
- 52 people
- Sponsor
- Ottawa Hospital Research Institute
Cardiac Toxicity, Leukemia
Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Cardiac Toxicity, Leukemia, Lymphoma
- Trial name
- T-Cell #4 (NCT01230983)
- Testing
- asparaginase, cytarabine, dexrazoxane hydrochloride
- Volunteers
- 573 people
- Sponsor
- Children's Oncology Group
Cardiac Toxicity
Race Difference Moxifloxacin-induced QT Prolongation Between Healthy Chinese and Caucasian Volunteers
A double-center, randomized, double-blinded, 2-way crossover, placebo-controlled Study: Comparison of single oral dose 400mg Moxifloxacin-induced QT prolongation between healthy Chinese volunteers and Caucasian Volunteers Study…
- Trial name
- NCT02119091
- Testing
- Moxifloxacin
- Where
- 2 sites in United States, China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Haiyan Li
Cardiotoxicity, Osteosarcoma
Evaluation of Myocardial Injury After Anthracycline Chemotherapy in Osteosarcoma Patients Using CMR
using a contrast-enhanced (CE) cardiac magnetic resonance imaging(CMR) which included the measurement of T1 mapping, T2 mapping, T2* mapping and late gadolinium enhancement(LGE) sequences, as well as LVEF and extracellular…
- Conditions
- Cardiotoxicity, Osteosarcoma, Myocardial Injury, Chemotherapy Induced Systolic Dysfunction
- Trial name
- NCT04461223
- Testing
- contrast-enhanced cardiac magnetic resonance imaging(MAGNETOM Aera 1.5T)
- Where
- China
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Breast Neoplasms
The Impact of Chronic Mitochondrial Antioxidant Supplementation on CardiovascularToxicity in Breast Cancer Patients
Investigate the protective effect of chronic MitoQ supplementation on cardiovascular toxicity induced by doxorubicin-based adjuvant chemotherapy in breast cancer patients.
- Trial name
- NCT05146843
- Testing
- Mitoquinone
- Volunteers
- 44 people
- Sponsor
- D'Or Institute for Research and Education